StoxAurobindo Pharma vs Max Healthcare Institute: share price & financials comparison
NSE: AUROPHARMA vs MAXHEALTH · Healthcare · as of 06 Nov 2026
Both prices rebased to 100 at the start of the selected period.
Aurobindo Pharma vs Max Healthcare Institute at a glance
Aurobindo Pharma (AUROPHARMA) has a market capitalisation of ₹1,03,572 Cr, against ₹90,907 Cr for Max Healthcare Institute (MAXHEALTH). Over the past year Aurobindo Pharma has returned +61.9%, compared with -21.5% for Max Healthcare Institute. On valuation, Aurobindo Pharma trades at a lower P/E of 26.0 versus 65.8. Max Healthcare Institute earns a higher return on equity (12.2% vs 10.1%). Aurobindo Pharma comes out ahead on size, valuation, growth, financial health, momentum and technicals. Max Healthcare Institute comes out ahead on profitability. Across the scored metrics below, Aurobindo Pharma leads on 12 and Max Healthcare Institute on 5. On StoxGud's 10-point checklist, Aurobindo Pharma scores 9/10 and Max Healthcare Institute scores 3/10.
| Metric | Aurobindo Pharma | Max Healthcare Institute |
|---|---|---|
| Size | ||
| Market cap | ₹1,03,572 Cr | ₹90,907 Cr |
| Revenue (latest FY) | ₹33,653 Cr | ₹8,373 Cr |
| Net profit (latest FY) | ₹3,505 Cr | ₹1,442 Cr |
| Valuation | ||
| P/E | 26.0 | 65.8 |
| P/B | 2.63 | 8.02 |
| Dividend yield | 0.22% | 0.16% |
| Profitability | ||
| Return on equity | 10.1% | 12.2% |
| Net profit margin | 10.8% | 15.1% |
| Operating margin | 20.5% | 26.8% |
| Growth | ||
| Revenue growth (YoY) | +23.9% | +20.3% |
| Net profit growth (YoY) | +32.7% | -15.5% |
| Revenue CAGR (multi-year) | +6.3% | +27.3% |
| Financial health | ||
| Debt to equity | 0.21 | 0.33 |
| Momentum | ||
| 1-month return | +7.0% | +2.9% |
| 1-year return | +61.9% | -21.5% |
| 3-year CAGR | +27.2% | +16.3% |
| 5-year CAGR | +21.8% | +22.5% |
| 10-year CAGR | +8.9% | — |
| Distance from 52W high | +0.0% | -20.9% |
| Technicals | ||
| RSI (14) | 67 | 79 |
| Price vs 200-day avg | +22.4% | -7.6% |
Highlighted cells lead on that metric. Market cap, revenue and RSI are shown for context and not scored.
10-point checklist side by side
| Check | Aurobindo Pharma | Max Healthcare Institute |
|---|---|---|
| Price above 50-day average | ✓ | ✗ |
| Price above 200-day average | ✓ | ✗ |
| 50-day average above 200-day (uptrend) | ✓ | ✗ |
| RSI in healthy 40–70 zone | ✓ | ✗ |
| Positive 1-year return | ✓ | ✗ |
| Return on equity above 15% | ✗ | ✗ |
| Debt to equity below 1 | ✓ | ✓ |
| Revenue growing year on year | ✓ | ✓ |
| Net profit margin above 10% | ✓ | ✓ |
| P/E below industry median | ✓ | ✗ |
| Score | 9/10 | 3/10 |
A rules-based screen for education only — not a buy or sell recommendation.
FAQs
Which is bigger, Aurobindo Pharma or Max Healthcare Institute?
Aurobindo Pharma has a market cap of ₹1,03,572 Cr and Max Healthcare Institute has a market cap of ₹90,907 Cr as of 06 Nov 2026.
Which has a lower P/E, Aurobindo Pharma or Max Healthcare Institute?
Aurobindo Pharma has the lower P/E: Aurobindo Pharma trades at 26.0 and Max Healthcare Institute at 65.8.
Which gave better returns in the last year, Aurobindo Pharma or Max Healthcare Institute?
Aurobindo Pharma did better: Aurobindo Pharma returned +61.9% and Max Healthcare Institute returned -21.5% over one year.
Is Aurobindo Pharma or Max Healthcare Institute a better buy?
StoxGud does not give buy or sell recommendations. On our rules-based checklist Aurobindo Pharma scores 9/10 and Max Healthcare Institute scores 3/10; compare valuation, profitability, growth and momentum above and consult a SEBI-registered adviser.